Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Calvez

Showing results (171-180 of 329) with videos related to

Pageof 33
Sort By:
AIDS Research and Human Retroviruses|November 26, 2014
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological ResponseCathia Soulie, Gilles Peytavin, Charlotte Charpentier, et al.
The Journal of Antimicrobial Chemotherapy|September 8, 2012
Pitfalls of HIV genotypic tropism testing after treatment interruptionMarc Wirden, Cathia Soulié, Slim Fourati, et al.
Journal of Medical Virology|October 20, 2012
Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropismCathia Soulié, Charlotte Charpentier, Philippe Flandre, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 27, 2017
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral loadMarc Wirden, Lucile Larrouy, Nadia Mahjoub, et al.
The Journal of Antimicrobial Chemotherapy|February 16, 2019
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimenMarine Perrier, Louise Castain, Leslie Regad, et al.
The Journal of Antimicrobial Chemotherapy|April 9, 2011
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patientsIsabelle Malet, Marc Wirden, Slim Fourati, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2012
Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapySidonie Lambert-Niclot, Philippe Flandre, Marc-Antoine Valantin, et al.
AIDS (London, England)|July 18, 2015
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremiaAmélie Guihot, Chiara Dentone, Lambert Assoumou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2013
A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletionCaroline Petitdemange, Abla Achour, Stefania Dispinseri, et al.
AIDS (London, England)|January 10, 2014
Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartmentsSlim Fourati, Sidonie Lambert-Niclot, Cathia Soulie, et al.
Pageof 33

Showing results (171-180 of 329) with videos related to

Sort By:
Pageof 33
AIDS Research and Human Retroviruses|November 26, 2014
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological ResponseCathia Soulie, Gilles Peytavin, Charlotte Charpentier, et al.
The Journal of Antimicrobial Chemotherapy|September 8, 2012
Pitfalls of HIV genotypic tropism testing after treatment interruptionMarc Wirden, Cathia Soulié, Slim Fourati, et al.
Journal of Medical Virology|October 20, 2012
Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropismCathia Soulié, Charlotte Charpentier, Philippe Flandre, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 27, 2017
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral loadMarc Wirden, Lucile Larrouy, Nadia Mahjoub, et al.
The Journal of Antimicrobial Chemotherapy|February 16, 2019
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimenMarine Perrier, Louise Castain, Leslie Regad, et al.
The Journal of Antimicrobial Chemotherapy|April 9, 2011
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patientsIsabelle Malet, Marc Wirden, Slim Fourati, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2012
Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapySidonie Lambert-Niclot, Philippe Flandre, Marc-Antoine Valantin, et al.
AIDS (London, England)|July 18, 2015
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremiaAmélie Guihot, Chiara Dentone, Lambert Assoumou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2013
A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletionCaroline Petitdemange, Abla Achour, Stefania Dispinseri, et al.
AIDS (London, England)|January 10, 2014
Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartmentsSlim Fourati, Sidonie Lambert-Niclot, Cathia Soulie, et al.
Pageof 33